Agni Bio Presents Preclinical Data on AGB201 at AACR Immuno-Oncology Conference 2026

South San Francisco, CA — February 9, 2026 — Agni Bio, Inc., a biotechnology company focused on developing innovative immunotherapies for cancer, today announced the presentation of new preclinical data for AGB201 at the AACR Immuno-Oncology Conference 2026, held February 18–21, 2026 in Los Angeles and organized by the American Association for Cancer Research.

The poster, titled “AGB201, a first-in-class LTβR x EDB bispecific antibody, induces EDB-dependent tertiary lymphoid structure formation and robust anti-tumor activity,” highlights the therapeutic potential of AGB201, a novel bispecific antibody designed to conditionally activate lymphotoxin beta receptor (LTβR) signaling within the tumor microenvironment.

Key Highlights from the Presentation:

• First-in-class mechanism: AGB201 targets the oncofetal antigen EDB, a splice variant of fibronectin broadly expressed in the extracellular matrix of solid tumors but largely absent in normal tissues.
• Conditional immune activation: The molecule drives EDB-dependent activation of canonical and non-canonical NF-κB pathways, enabling localized immune stimulation.
• Induction of tertiary lymphoid structures (TLS): AGB201 promotes chemokine signaling (including CXCL13, CCL19, and CCL21) associated with TLS formation, which is linked to improved responses to immunotherapy.
• Enhanced immune cell trafficking: In vitro studies demonstrated increased monocyte transendothelial migration in an EDB-dependent manner.
• Robust in vivo efficacy: In syngeneic tumor models, AGB201 showed strong monotherapy activity, including complete tumor regressions, and further enhanced efficacy in combination with checkpoint inhibitors such as anti–PD-1 and anti–CTLA-4.
• Durable immune memory: Rechallenge studies indicated the generation of long-term anti-tumor immune memory in treated animals.

“These data underscore the potential of AGB201 to reprogram the tumor microenvironment and expand the benefit of immunotherapy to patients who do not respond to current checkpoint inhibitors,” said Matt Lorenzi PhD, Agni’s Chief Scientific Officer and Board Member. Lorenzi continued, “By selectively activating LTβR signaling in EDB-positive tumors, AGB201 represents a promising new approach to drive durable anti-tumor immunity and expand combination strategies with checkpoint-based therapies.”

AGB201 is part of Agni Bio’s broader platform of conditionally active bispecific antibodies designed to precisely modulate immune pathways within tumors while minimizing systemic toxicity.

About Agni Bio
Agni Bio is a biotechnology company based in South San Francisco, CA, focused on developing innovative therapies to address unmet needs in oncology and autoimmune diseases. The company leverages its proprietary bispecific antibody platforms to advance the next frontier in immune cell redirection therapy.

Contact:
Agni Bio, Inc.
communications@agnibiotx.com